ly3372689 ly3372689 ly3372689 is a drug candidate molecule under investigation to treat alzheimer's disease. it targets the enzyme o-glcnacase. its result is to reduce formation of tau protein tangles. ly3372689 names iupac name n-piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide identifiers 3d model (jsmol) interactive image pubchem cid 135271363 inchi inchi=1s/c16h22fn5o3s/c1-9-6-12(24-8-14-19-11(3)25-21-14)4-5-22(9)7-13-15(17)20-16(26-13)18-10(2)23/h9,12h,4-8h2,1-3h3,(h,18,20,23)key: frvxhwnhgwutqo-uhfffaoysa-n smiles cc(nc1=nc(f)=c(cn2cc(occ3=noc(c)=n3)c2c)s1)=o properties chemical formula c16h22fn5o3s molar mass 383.44 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references a molecule containing radioactive fluorine was used with a pet scan to show that ly3372689 binds in the human brain. eli lilly and company is recruiting subjects for a clinical trial. some hospitals in australia: st vincent's hospital, sydney hornsby ku-ring-gai hospital, the prince charles hospital, the queen elizabeth hospital, adelaide, box hill hospital, and delmont private hospital are involved. results of the trial are expected by june 2024. chemical the molecule contains three rings: thiazole, piperidine and oxadiazole. other functional groups included are an ether, acetamide, and a fluoride.